320 results on '"Hansen, Doris"'
Search Results
2. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
3. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience
4. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
5. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
6. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
7. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
8. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
9. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
10. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature
11. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience
12. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
13. Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
14. BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.
15. Toxicity of CAR T-Cell Therapy for Multiple Myeloma
16. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
17. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study
18. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
19. Impact of Renally Adjusted Methotrexate Dosing on Safety and Efficacy Outcomes in Allogeneic Hematopoietic Cell Transplant Patients
20. Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for Plasma Cell Leukemia (PCL): A Multicenter Experience
21. Unveiling the Digital Landscape of CAR-T Therapies in Multiple Myeloma Using Social Media Insights
22. Outcomes of Haploidentical Stem Cell Transplant Recipients with HHV-6 Reactivation Receiving Antiviral Therapy
23. Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States
24. Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial
25. Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd Prevention
26. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
27. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.
28. Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center Experience
29. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation
30. Toxicities associated with adoptive cellular therapies
31. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium
32. The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review
33. Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium
34. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
35. MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
36. P-464 Treatment decision-making in patients diagnosed with multiple myeloma
37. POSTER: MM-619 Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States
38. MM-619 Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States
39. POSTER: CT-452 Outpatient vs Inpatient Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Cancer Patients: Systematic Literature Review
40. P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience
41. P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States
42. CT-452 Outpatient vs Inpatient Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Cancer Patients: Systematic Literature Review
43. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
44. P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium
45. POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
46. P1540: COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE
47. PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
48. Reply to R. Chakraborty et al
49. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
50. Impact of weight and creatinine adjustments on the accuracy of Cockcroft‐gault equation in hematopoietic cell transplant patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.